+ +

•  

   

     Western blot analysis of PTPN1/2 expression in HepG2 cell lysate.    

  
  

•  

   

     Immunoprecipitate (IP) analysis using the Antibody at 1:50 dilution. (wb at 1:1K dilution)    

  
  

PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) and PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) are intracellular tyrosine phosphatases that play critical roles in regulating cellular signaling pathways. Both belong to the class I family of protein tyrosine phosphatases (PTPs) and share structural homology, including a conserved catalytic domain. PTPN1. also known as PTP1B, is widely expressed and negatively regulates insulin and leptin signaling, making it a therapeutic target for diabetes and obesity. PTPN2. or TCPTP, is highly expressed in hematopoietic cells and modulates immune responses, growth factor signaling, and inflammation. Dysregulation of these phosphatases is linked to cancer, metabolic disorders, and autoimmune diseases.

Antibodies targeting PTPN1/2 are essential tools for studying their expression, localization, and function in physiological and pathological contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein levels in tissues or cell lines. Due to the structural similarity between PTPN1 and PTPN2. antibody specificity is crucial; rigorous validation using knockout controls or siRNA knockdown is required to avoid cross-reactivity. Research applications include investigating their roles in insulin resistance, tumor suppression, or immune checkpoint regulation. Additionally, PTPN1/2 inhibitors are under development for therapeutic use, driving demand for reliable antibodies to assess target engagement and pharmacodynamic effects in preclinical studies.